Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act

Contemporary Clinical Trials

Volumn 37, Issue 2, 2014, Pages 219-224

  Logvinov, Ilana ^a  

^a MAYO CLINIC   (United States)

Author keywords

Clinical trials; Compliance; Industries; Research reporting; TEST Act; Transparency

Indexed keywords

ACT; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; CONSUMER HEALTH INFORMATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE INDUSTRY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INTERPERSONAL COMMUNICATION; LAW; MANDATORY REPORTING; MEDICAL LITERATURE; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PRIVACY; PROTOCOL COMPLIANCE; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; PUBLISHING; REGISTRATION; RESEARCH ETHICS; STUDY DESIGN; TRIAL AND EXPERIMENTAL STUDIES TRANSPARENCY ACT; UNITED STATES; DOCUMENTATION; LEGISLATION AND JURISPRUDENCE; METHODOLOGY; ORGANIZATION AND MANAGEMENT;

NEW DRUG;

CLINICAL TRIALS AS TOPIC; CONFIDENTIALITY; DISCLOSURE; DOCUMENTATION; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HEALTH POLICY; HUMANS; RESEARCH DESIGN; UNITED STATES;

EID: 84893036478     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.01.001     Document Type: Article

References (41)

1. Castellani J. Are clinical trial data shared sufficiently today? Yes. BMJ 2013, 347:f1881. 10.1136/bmj.f1881.
2. Antonelli M., Mercurio G. Reporting, access, and transparency: better infrastructure of clinical trials. Crit Care Med 2009 Jan, 37(Suppl. 1):S178-S183. 10.1097/CCM.0b013e31819207bb.
3. Sim I., Chan A.W., Gulmezoglu A.M., Evans T., Pang T. Clinical trial registration: transparency is the watchword. Lancet May 2006, 367(9523):1631-1633. 10.1016/S0140-6736(06)68708-4.
4. Krleza-Jeric K., Lemmens T., Reveiz L., Cuervo L.G., Bero L.A. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica Jul. 2011, 30(1):87-96.
5. Ross J.S., Gross C.P., Krumholz H.M. Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health Jan. 2012, 102(1):72-80. 10.2105/AJPH.2011.300187.
6. World Medical Association, Inc WMA Declaration of Helsinki-ethical principles for medical research involving human subjects Available from, [October 7, 2013]. http://www.wma.net/en/30publications/10policies/b3/.
7. Prayle A.P., Hurley M.N., Smyth A.R. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 2012, 344:d7373.
8. US Food and Drug Administration CDER: The Consumer Watchdog for Safe and Effective Drugs Available from, [September 27, 2013]. http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143462.htm.
9. Investigational device exemptions 1980, Stat. § 812.3.
10. Investigational new drug application 1987, Stat. § 312.3.
11. Archer J. Traveling the road to clinical trial transparency 2013.
12. Valentine J.E., Clissold D.B. Striding towards greater access to clinical trials data and results 2013.
13. Zarin D.A. Participant-level data and the new frontier in trial transparency. N Engl J Med 2013 Aug 1, 369(5):468-469. 10.1056/NEJMe1307268.
14. Markey E.H.R. TEST Act. Civic Impulse, LLS; 2013 Available from, [September 27, 2013]. https://www.govtrack.us/congress/bills/113/hr2031.
15. Markey E.H.R. TEST Act 113th Congress (2013-2014) Congress.gov; 2013 Available from, [September 27, 2013]. http://beta.congress.gov/bill/113th/house-bill/2031.
16. Drazen J.M. Transparency for clinical trials-the TEST Act. N Engl J Med 2012 Aug 30, 367(9):863-864. 10.1056/NEJMe1209433.
17. Brennan Z. US House bill aims to expand release of clinical trials data Available from, [September 27, 2013]. http://www.in-pharmatechnologist.com/Regulatory-Safety/US-House-Bill-Aims-to-Expand-Release-of-Clinical-Trials-Data.
18. Gaffney A. US would see clinical trials reporting transparency under new legislation. Regulatory Affairs Professionals Society Available from, [September 27, 2013]. http://www.raps.org/focus-online/news/news-article-view/article/3473/us-would-see-clinical-trials-reporting-transparency-under-new-legislation.aspx.
19. Bourgeois F.T., Murthy S., Mandl K.D. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010 Aug 3, 153(3):158-166.
20. Mintzes B., Lexchin J., Sutherland J.M., et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med 2013 Oct, 28(10):1368-1375. 10.1007/s11606-013-2411-7.
21. Goldacre B., Heneghan C., Godlee F. Missing trials briefing note Available from. http://www.alltrials.net/wp-content/uploads/2013/01/Missing-trials-briefing-note.pdf.
22. Guo S.W., Evers J.L. Lack of transparency of clinical trials on endometriosis. Obstet Gynecol 2013 Jun, 121(6):1281-1290. 10.1097/AOG.0b013e318291f299.
23. Ross J.S., Tse T., Zarin D.A., Xu H., Zhou L., Krumholz H.M. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ 2012, 344:d7292. 10.1136/bmj.d7292.
24. Zarin D.A., Tse T., Williams R.J., Califf R.M., Ide N.C. The ClinicalTrials.gov results database-update and key issues. N Engl J Med 2011 Mar 3, 364(9):852-860.
25. Gopal R.K., Yamashita T.E., Prochazka A.V. Research without results: inadequate public reporting of clinical trial results. Contemp Clin Trials 2012 May, 33(3):486-491. 10.1016/j.cct.2012.02.001.
26. Goldacre B. Are clinical trial data shared sufficiently today? No. BMJ 2013, 347:f1880. 10.1136/bmj.f1880.
27. Viergever R.F., Ghersi D. The quality of registration of clinical trials. PLoS One 2011, 6(2):e14701. 10.1371/journal.pone.0014701.
28. Loewenstein G., Cain D.M., Sah S. The limits of transparency: pitfalls and potential of disclosing conflicts of interest. Am Econ Rev 2011, 101(3):423-428. 10.1257/aer.101.3.423.
29. Yarborough M.A. Increasing enrollment in drug trials: the need for greater transparency about the social value of research in recruitment efforts. Mayo Clin Proc 2013 May, 88(5):442-445. 10.1016/j.mayocp.2013.03.001.
30. Denegri S., Faure H. It's plain and simple: transparency is good for science and in the public interest. Trials 2013, 14:215. 10.1186/1745-6215-14-215.
31. Andanda P. Managing intellectual property rights over clinical trial data to promote access and benefit sharing in public health. IIC Int Rev Intellect Prop Compet Law 2013, 44(2):140-177. 10.1007/s40319-012-0016-z.
32. Hawkes N. Industry and drug regulators disagree on which data should remain confidential. BMJ 2013, 347:f5390. 10.1136/bmj.f5390.
33. World Trade Organization Agreement on trade-related aspects of intellectual property rights Available from, [October 14, 2013]. http://www.wto.org/english/tratop_e/trips_e/t_agm0_e.htm.
34. Access to clinical-trial data and transparency Workshop report Available from. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/12/WC500135841.pdf.
35. European Medicines Agency ICH Topic E 5 (R1) ethnic factors in the acceptability of foreign clinical data Available from, [December 30,2013]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf.
36. Kmietowicz Z. GSK backs campaign for disclosure of trial data. BMJ 2013, 346:f819. 10.1136/bmj.f819.
37. Hawkes N. Full access to trial data holds many benefits and a few pitfalls, conference hears. BMJ 2012, 344:e3723. 10.1136/bmj.e3723.
38. Silverman E. Once again, a bill to strengthen patient safety in clinical trials 2013.
39. Astra Zeneca Transparency of trial information Available from, [September 27, 2013]. http://www.astrazeneca.com/Responsibility/Research-ethics/Clinical-trials/Transparency-of-trial-information.
40. Roche Roche Global Policy on Sharing of Clinical Trials Data Available from, [September 27,2013]. http://www.roche-trials.com/dataSharingPolicy.action.
41. Department of Health and Human Services 45 CFR Parts 160 and 164: Modifications to the HIPAA privacy, security, enforcement, and breach notification rules under the Health Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act; other modifications to the HIPAA rules. Fed Regist 2013, 78(17):5566-5702. [http://www.gpo.gov/fdsys/pkg/FR-2013-01-25/pdf/2013-01073.pdf].